Linkedin Youtube
Launch Digital Edition

Webinars and Commercial Conversations — Register Now

Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.

Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace Directory

Thermo Fisher launches IVDR-compliant capillary electrophoresis system

May 2025—Thermo Fisher Scientific has introduced the Applied Biosystems SeqStudio Flex Dx genetic analyzer, an IVDR-compliant capillary electrophoresis system for Sanger sequencing and fragment analysis in targeted genomic testing. The system includes three operating modes—in vitro diagnostic use, investigational use only, and research use only—and is available in eight- and 24-capillary configurations. It features four-plate capacity, continuous plate loading with auto-spectral calibration capabilities, and urgent sample reprioritization.

Verichem electrolyte testing reference materials

May 2025—Verichem Laboratories offers liquid stable, multianalyte kits of clinical reference materials intended for the calibration verification of electrolyte assays. The materials are designed to be treated as patient samples for use with systems using flame photometer, direct and indirect ion-selective electrode, or standard enzymatic/colorimetric testing methods. The electrolyte standard kit contains the analytes chloride, ionized calcium, lithium, potassium, and sodium and features a 21-month stability claim; the ISE standard kit contains chloride, lithium, potassium, and sodium and offers an 18-month stability claim. Carbon dioxide assays are covered by the CO2 standard kit and the standalone, ultrahigh CO2 standard level F, which have a 15-month stability claim.

Vitro appoints Biocare Medical as exclusive U.S. distributor

May 2025—Vitro announced it has appointed Biocare Medical (Pacheco, Calif.) as the exclusive distributor of its NeoPath Pro automated staining instrument in the United States. NeoPath Pro is a high-throughput platform with a 42-slide capacity, supporting immunohistochemistry, in situ hybridization, and fluorescence in situ hybridization. The instrument was launched at the USCAP annual meeting in Boston, March 22–27. Vitro is headquartered in Spain.

Vitestro collaborates with Northwestern Medicine

May 2025—Northwestern Medicine and Vitestro announced a multiyear collaboration to advance automation in phlebotomy. As part of the collaboration, Northwestern Medicine will participate in a multicenter clinical trial validating the performance and safety of Vitestro’s Aletta, an autonomous robotic phlebotomy device. The goal of the study is to generate key clinical evidence to support the adoption of automated phlebotomy as a scalable solution for U.S. hospital and outpatient blood draw centers.

Revolutionizing cancer diagnosis: the game-changing role of digital pathology and artificial intelligence

May 2025—The following is an extended release prepared by Agilent Technologies: Pathology plays a critical role in cancer care, encompassing the development of new treatments, diagnosis, staging, grading of disease, and clinical decision-making. While histopathological slides of tissue biopsies using hematoxylin and eosin staining and immunohistochemical staining remain central to this process, the rise of precision medicine testing is placing greater demands on pathology labs.

Vitestro unveils Aletta robotic phlebotomy device

April 2025—Vitestro unveiled its CE-marked Aletta Autonomous Robotic Phlebotomy Device. Using AI-driven ultrasound guidance, robotic precision, and full automation, Aletta is designed to perform the entire blood draw process, from applying a tourniquet and preparing the skin to vein identification, venipuncture, automated tube handling, and bandage application. The device integrates advanced AI-driven Doppler ultrasound technology to optimize vein selection and needle placement.

ARUP expands AI-augmented screening tool

April 2025—ARUP Laboratories announced the expansion of its AI-augmented screening tool for the detection of human gastrointestinal parasites to include wet-mount slides. The tool uses scanned images to screen and eliminate negative specimens. It aims to reduce ergonomic stressors on laboratory staff, decrease turnaround time, and increase capacity.

Diasorin C. auris assay launched in countries accepting the CE mark

April 2025—Diasorin announced the launch of its Simplexa C. auris Direct kit in all countries that accept the CE mark. The real-time polymerase chain reaction assay is used for the direct in vitro qualitative detection of C. auris DNA from a composite swab of the axilla and groin from patients suspected of C. auris colonization. The assay detects all six C. auris clades identified worldwide. Results are available in less than two hours on the Liaison MDX.

Advanced Instruments acquires Nova Biomedical

April 2025—Advanced Instruments, a subsidiary of Patricia Industries, announced the execution of a definitive agreement to acquire Nova Biomedical. Following the close of the transaction, Advanced Instruments and Nova Biomedical will merge and operate under the Nova Biomedical name. Byron Selman, president and CEO of Advanced Instruments, will lead the combined business, while Nova Biomedical founding shareholders Frank Manganaro, CEO, and Dr. Chung-Chang Young, EVP of R&D, will stay with the company in a consulting capacity.

MARKETPLACE

TRENDING